Long-term follow-up (FU) with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with metastatic non-small cell lung cancer (NSCLC), including special populations: CheckMate 817 (ESMO-IO 2026) - Oct 25, 2026 - Abstract #272P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Clinical • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Neal Ready; Clarisse Audigier-Valette; Jonathan W. Goldman; Enriqueta Felip; Tudor-Eliade Ciuleanu; Maria Rosario Garcia-Campelo; Kevin Jao; Fabrice Barlesi; Laszlo Urban; Jean-Sébastien Aucoin; Cristina Zannori; Karim Y. Vermaelen; Alessand ra Curioni-Fontecedro; David R. Spigel; Samreen Ahmed; Michele Maio; Swara Kasbekar; Angelic Acevedo; N an Hu; Luis Paz-Ares
|